“What’s more, one of the top obstacles that oncologists deal with today is the lack of scientific trial access for patients, which is due to the accessibility of more treatment alternatives overall.”TrialJectory’s work– driven by an extremely knowledgeable management group, made up of both oncology and technology specialists– is interfering with and reshaping how we think about traditional cancer care today,” concluded Bob Greene, from Contour Venture Partners. “Even more important, it is empowering clients to take back control of their treatment, and we look forward to enjoying TrialJectory’s platform continue to grow rapidly.